Action guide for community pharmacist in patients with hypertension and cardiovascular risk. Consensus Document
Keywords:
“Community Pharmacy Services”, “Pharmacy”, “Blood pressure determination”, “Hypertension”, “Blood Pressure Monitoring”Abstract
Arterial hypertension (AH) is an important health-related problem, as responsible for an important part of cardiovascular disorders. Moreover, AH is related to the development and progression of organ damage, which has indeed a negative influence in the cardiovascular prognosis of the individual. In Spain, AH is a frequent condition, affecting about 10 millions of the adult population.
Due to their accessibility and specific background on drug management, the community pharmacist could play a key role in the detection and follow-up of the hypertensive patient. To date, several guidelines on hypertension management have been released, although almost invariably have been addressed to the medical community. However, it has become more evident the need for a global management of hypertension and cardiovascular risk with the participation of several health-care providers, such as pharmacists and nurses, with the aim of improving cardiovascular prevention and the quality of life of subjects affected. The present document, particularly addressed to the community pharmacist, is intended to provide current knowledge with the aim of a better shared management of patients with hypertension and cardiovascular risk.
The present document pretends to serve as a tool for currently developed programs supporting the involvement of the community pharmacy in the care of patients with hypertension and cardiovascular risk. The document has been developed after a consensus between members from the Spanish Society of Hypertension, the Spanish Society of Community Pharmacy and the Research Group on Pharmaceutical Care from the University of Granada.
Downloads
References
Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002; 360: 1903-1913.
Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007; 25: 1105-1187.
De la Sierra A, Gorostidi M, Marin R, Redon J, Banegas JR, Armario P et al. Evaluación y tratamiento de la hipertensión arterial en España. Med Clin (Barc). 2008; 131: 104-116.
De la Sierra A. Valor de la presión de pulso como marcador de riesgo car¬diovascular. Med Clin (Barc). 2006; 126: 384-388.
Banegas JR, Rodriguez-Artalejo F, de la Cruz Troca JJ, Guallar-Castillon P, del Rey Calero J. Blood pressure in Spain: distribution, awareness, control, and benefits of a reduction in average pressure. Hypertension. 1998; 32: 998-1002.
Banegas JR, Rodriguez-Artalejo F, Ruilope LM, Graciani A, Luque M, de la Cruz-Troca JJ et al. Hypertension magnitude and management in the elderly population of Spain. J Hypertens. 2002; 20: 2157-2164.
Banegas J, Rodríguez-Artalejo F, Cruz J, de Andrés B, Rey J. Mortalidad relacionada con la presión arterial y la hipertensión en España. Med Clin (Barc). 1999; 112: 489-494.
Banegas JR, Segura J, Ruilope LM, Luque M, Garcia-Robles R, Campo C et al. Blood pressure control and physician management of hypertension in hospital hypertension units in Spain. Hypertension. 2004; 43: 1338-1344.
Banegas JR, Segura J, Sobrino J, Rodriguez-Artalejo F, de la Sierra A, de la Cruz JJ et al. Effectiveness of blood pressure control outside the medical setting. Hypertension. 2007; 49: 62-68.
Llisterri J, Rodríguez-Roca G, Alonso F, Banegas J, Barrios V, González D et al. Control de la presión arterial en la población hipertensa española atendida en Atención Primaria. Estudio PRESCAP 2006. Med Clin (Barc). 2008; 130: 681-7.
D’Agostino RB, Sr., Grundy S, Sullivan LM, Wilson P. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA. 2001; 286: 180-187.
Marrugat J, Subirana I, Comin E, Cabezas C, Vila J, Elosua R et al. Validity of an adaptation of the Framingham cardiovascular risk function: the VERIFICA Study. J Epidemiol Community Health. 2007; 61: 40-47.
Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003; 24: 987-1003.
Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). Eur Heart J. 2007; 28: 2375-2414.
Machado M, Bajcar J, Guzzo GC, Einarson TR. Sensitivity of patient outcomes to pharmacist interventions. Part II: Systematic review and meta-analysis in hypertension management. Ann Pharmacother. 2007; 41: 1770-1781.
Weber CA, Ernst ME, Sezate GS, Zheng S, Carter BL. Pharmacist-physician comanagement of hypertension and reduction in 24-hour ambulatory blood pressures. Arch Intern Med. 2010; 170: 1634-1639.
Yamada C, Johnson JA, Robertson P, Pearson G, Tsuyuki RT. Long-term impact of a community pharmacist intervention on cholesterol levels in patients at high risk for cardiovascular events: extended follow-up of the second study of cardiovascular risk intervention by pharmacists (SCRIP-plus). Pharmacotherapy. 2005; 25: 110-115.
Tobari H, Arimoto T, Shimojo N, Yuhara K, Noda H, Yamagishi K et al. Physician-pharmacist cooperation program for blood pressure control in patients with hypertension: a randomized-controlled trial. Am J Hypertens. 2010; 23: 1144-1152.
Machado M, Bajcar J, Guzzo GC, Einarson TR. Sensitivity of patient outcomes to pharmacist interventions. Part I: systematic review and meta-analysis in diabetes management. Ann Pharmacother. 2007; 41: 1569-1582.
Lee JK, Grace KA, Taylor AJ. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. JAMA. 2006; 296: 2563-2571.
Chabot I, Moisan J, Gregoire JP, Milot A. Pharmacist intervention program for control of hypertension. Ann Pharmacother. 2003; 37: 1186-1193.
Von Muenster SJ, Carter BL, Weber CA, Ernst ME, Milchak JL, Steffensmeier JJ et al. Description of pharmacist interventions during physician-pharmacist co-management of hypertension. Pharm World Sci. 2008; 30: 128-135.
Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil. 2007; 14(Suppl 2): S1-113.
Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens. 2009; 27: 2121-2158.
Maiques Galán A, Villar Álvarez F, Brotons Cuixart C, Torcal Laguna J, Orozco-Beltrán D, Navarro Pérez J et al. Recomendaciones preventivas cardiovasculares. Aten Primaria. 2007; 39(Suppl 3): 15-26.
O’Brien E, Pickering T, Asmar R, Myers M, Parati G, Staessen J et al. Working Group on Blood Pressure Monitoring of the European Society of Hypertension International Protocol for validation of blood pressure measuring devices in adults. Blood Press Monit. 2002; 7: 3-17.
Sabater-Hernández D, Sánchez-Villegas P, Lacampa P, Artiles-Campelo A, Jorge-Rodríguez ME, Faus MJ. Evaluation of the hypertensive state in treated patients: selection of appropriate blood pressure measurements per visit to the community pharmacy. Blood Press Monit. 2011; 16: 103-110.
Sabater-Hernandez D, Azpilicueta I, Sanchez-Villegas P, Amariles P, Baena MI, Faus MJ. Clinical value of blood pressure measurement in the community pharmacy. Pharm World Sci. 2010; 32: 552-558.
Sega R, Facchetti R, Bombelli M, Cesana G, Corrao G, Grassi G et al. Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population: follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study. Circulation. 2005; 111: 1777-1783.
Fagard RH, Van Den Broeke C, De Cort P. Prognostic significance of blood pressure measured in the office, at home and during ambulatory monitoring in older patients in general practice. J Hum Hypertens. 2005; 19: 801-807.
Verberk WJ, Kroon AA, Kessels AG, de Leeuw PW. Home blood pressure measurement: a systematic review. J Am Coll Cardiol. 2005; 46: 743-751.
Sabater-Hernández D, de la Sierra A, Sánchez-Villegas P, Baena M, Amariles P, Faus MJ. Magnitude of the white-coat effect in the community pharmacy setting. The MEPAFAR study. Am J Hypertens. Epub 2011 April 21. doi: 10.1038/ajh.2011.68.
Sendra-Lillo J, Sabater-Hernández D, Sendra-Ortola A, Martínez-Martínez F. Comparison of the white-coat effect in the community pharmacy versus the physician office. The PALMERA study. Blood Press Monit. 2011; 16: 62-66.
Parati G, Pickering TG. Home blood-pressure monitoring: US and European consensus. Lancet. 2009; 373: 876-878.
Parati G, Stergiou GS, Asmar R, Bilo G, de Leeuw P, Imai Y et al. European Society of Hypertension guidelines for blood pressure monitoring at home: a summary report of the Second International Consensus Conference on Home Blood Pressure Monitoring. J Hypertens. 2008; 26: 1505-1526.
Pickering TG, Miller NH, Ogedegbe G, Krakoff LR, Artinian NT, Goff D. Call to action on use and reimbursement for home blood pressure monitoring: a joint scientific statement from the American Heart Association, American Society Of Hypertension, and Preventive Cardiovascular Nurses Association. Hypertension. 2008; 52: 10-29.
Parati G, Stergiou GS, Asmar R, Bilo G, de Leeuw P, Imai Y et al. European Society of Hypertension Practice Guidelines for home blood pressure monitoring. J Hum Hypertens. 2010; 24: 779-785.
Mallion JM, Baguet JP, Mancia G. European Society of Hypertension Scientific Newsletter: Clinical value of ambulatory blood pressure monitoring. J Hypertens. 2006; 24: 2327-2330.
Sabater-Hernández D, Fikri-Benbrahim O, Faus MJ. Utilidad de la monitorización ambulatoria de la presión arterial en la toma de decisiones clínicas. Med Clin (Barc). 2010; 135: 23-29.
Fagard RH, Celis H, Thijs L, Staessen JA, Clement DL, De Buyzere ML et al. Daytime and nighttime blood pressure as predictors of death and cause-specific cardiovascular events in hypertension. Hypertension. 2008; 51: 55-61.
White WB. Cardiovascular risk and therapeutic intervention for the early morning surge in blood pressure and heart rate. Blood Press Monit. 2001; 6: 63-72.
Kario K, Pickering TG, Umeda Y, Hoshide S, Hoshide Y, Morinari M et al. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. Circulation. 2003; 107: 1401-1406.
Mancia G, Bombelli M, Facchetti R, Madotto F, Corrao G, Trevano FQ et al. Long-term prognostic value of blood pressure variability in the general population: results of the Pressioni Arteriose Monitorate e Loro Associazioni Study. Hypertension. 2007; 49: 1265-1270.
Kikuya M, Ohkubo T, Metoki H, Asayama K, Hara A, Obara T et al. Day-by-day variability of blood pressure and heart rate at home as a novel predictor of prognosis: the Ohasama study. Hypertension. 2008; 52: 1045-1050.
Vinyoles E. Presión ambulatoria y enfermedad cardiovascular. Hipertens riesgo vasc 2008; 25(Suppl 2): 35-43.
Vanelli M, Pedan A, Liu N, Hoar J, Messier D, Kiarsis K. The role of patient inexperience in medication discontinuation: a retrospective analysis of medication nonpersistence in seven chronic illnesses. Clin Ther. 2009; 31: 2628-2652.
Dickinson HO, Mason JM, Nicolson DJ, Campbell F, Beyer FR, Cook JV et al. Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials. J Hypertens. 2006; 24: 215-233.
Lobos JM, Royo-Bordonada MA, Brotons C, Alvarez-Sala L, Armario P, Maiques A et al. Guía europea de Prevención Cardiovascular en la Práctica Clínica. Adaptación española del Comité Español Interdisciplinario para la Prevención Cardiovascular 2008. Rev Esp Salud Publica. 2008; 82: 581-616.
Sabater-Hernández D, Baena MI, Sánchez-Villegas P, Amariles P, García-Corpas JP, Faus MJ et al. Prevalence of masked and isolated clinic hypertension in treated hypertensive patients in a community pharmacy setting. Preliminary results of the blood pressure measurement study in community pharmacies: The MEPAFAR study [Abstract]. Pharm World Sci. 2010; 32: 262-263.
Hermida RC, Ayala DE, Fernandez JR, Calvo C. Chronotherapy improves blood pressure control and reverts the nondipper pattern in patients with resistant hypertension. Hypertension. 2008; 51: 69-76.
Merino Sanchez J, Gil Guillen VF. Cronobiología, cronoterapia y riesgo vascular. Rev Clin Esp. 2005; 205: 283-286.
Stergiou G, Mengden T, Padfield PL, Parati G, O’Brien E. Self monitoring of blood pressure at home. BMJ. 2004; 329: 870-871.
Cappuccio FP, Kerry SM, Forbes L, Donald A. Blood pressure control by home monitoring: meta-analysis of randomised trials. BMJ. 2004; 329: 145.
Burke JM, Miller WA, Spencer AP, Crank CW, Adkins L, Bertch KE et al. Clinical pharmacist competencies. Pharmacotherapy. 2008; 28: 806-815.
Comité de Consenso. Tercer Consenso de Granada sobre problemas relacionados con los medicamentos (PRM) y resultados negativos asociados a la medicación (RNM). Ars Pharm. 2007; 48: 5-17.
Burnier M. Medication adherence and persistence as the cornerstone of effective antihypertensive therapy. Am J Hypertens. 2006; 19: 1190-1196.
Rodriguez Chamorro MA, Garcia-Jimenez E, Amariles P, Rodriguez Chamorro A, Faus MJ. Revisión de tests de medición del cumplimiento terapéutico utilizados en la práctica clínica. Aten Primaria 2008; 40: 413-418.
Gil V, Pineda M, Martinez JL, Belda J, Santos ML, Merino J. Validez de 6 métodos indirectos para valorar el cumplimiento terapéutico en hipertensión arterial. Med Clin (Barc). 1994; 102: 532-536.
Márquez Contreras E, Gil Guillen V, Casado Martinez JJ, Martel Claros N, De la Figuera von Wichmann M, Martin de Pablos JL et al. Análisis de los estudios publicados sobre el incumplimiento terapéutico en el tratamiento de la hipertensión arterial en España entre los años 1984 y 2005. Aten Primaria. 2006; 38: 325-332.
Márquez Contreras E. Evaluación del incumplimiento en la práctica clínica. Hipertens riesgo vasc. 2008; 25: 205-213.
Morrison A, Wertheimer A, Berger M. Interventions to improve antihypertensive drug adherence:a quantitaive review of trials. Formulary. 2000; 35: 234-255.
Downloads
Published
How to Cite
Issue
Section
License
The articles, which are published in this journal, are subject to the following terms in relation to the rights of patrimonial or exploitation:
- The authors will keep their copyright and guarantee to the journal the right of first publication of their work, which will be distributed with a Creative Commons BY-NC-SA 4.0 license that allows third parties to reuse the work whenever its author, quote the original source and do not make commercial use of it.
b. The authors may adopt other non-exclusive licensing agreements for the distribution of the published version of the work (e.g., deposit it in an institutional telematic file or publish it in a monographic volume) provided that the original source of its publication is indicated.
c. Authors are allowed and advised to disseminate their work through the Internet (e.g. in institutional repositories or on their website) before and during the submission process, which can produce interesting exchanges and increase citations of the published work. (See The effect of open access).
